Gilead Pays $3.15B for Tubulis, Bolstering ADC Oncology Pipeline
Event summary
- Gilead completed its $3.15B acquisition of Tubulis, a German ADC developer, with up to $1.85B in milestone payments.
- Tubulis’ lead asset TUB-040 targets platinum-resistant ovarian cancer and NSCLC.
- The deal establishes The Tubulis ADC Innovation Center in Munich to advance next-gen ADC technologies.
- Gilead gains access to Tubulis’ platform for selective payload delivery to tumors.
The big picture
Gilead’s acquisition of Tubulis underscores the biopharma giant’s push to dominate next-generation ADC technologies, a key growth area in oncology. The $3.15B upfront payment signals confidence in Tubulis’ platform, which could reshape how payloads are delivered to tumors. This deal follows Gilead’s $32B U.S. investment pledge in 2025, reinforcing its commitment to expanding its oncology footprint beyond HIV and viral hepatitis.
What we're watching
- Pipeline Integration
- How Gilead will integrate Tubulis’ ADC platform with its existing oncology portfolio, particularly Kite’s cell therapy focus.
- Clinical Momentum
- The pace at which TUB-040 advances through Phase I/IIa trials in ovarian cancer and NSCLC.
- Execution Risk
- Whether Gilead can deliver on the $1.85B in contingent milestone payments tied to Tubulis’ clinical and commercial milestones.
Related topics